All In Biotech

Free tool

FAERS Monitor: Contepo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212271 or its brand name (Contepo, Fosfomycin Disodium). Reports on generic versions are filed under their own applications.

Reports

4

Serious

4

100% of reports

Hospitalization

4

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • acute kidney injury2
  • ascites2
  • chills2
  • contusion2
  • cystitis2
  • dry mouth2
  • fatigue2
  • gastroenteritis2
  • haematuria2
  • lipase increased2
  • liver function test increased2
  • malignant neoplasm progression2
  • nausea2
  • oedema peripheral2
  • pruritus2

Reports by year received

View as table
YearReports
20161
20191
20201
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lipase increased21372.9515.11,542
gastroenteritis2720.4270.3808
liver function test increased2489.9183.8549
ascites2357.7134.3400
cystitis2330.2123.9369
haematuria2307.1115.3343
dry mouth2129.648.6143
contusion2109.241.0120
malignant neoplasm progression2102.738.5113
chills289.733.798
oedema peripheral286.332.495
acute kidney injury268.725.875
pruritus227.410.328
fatigue213.55.113
nausea213.35.013

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.